Litcius/Paper detail

Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an <i>in-silico</i> approach

Rupesh V. Chikhale, Shailendra Gurav, Rajesh B. Patil, Saurabh K. Sinha, Satyendra K. Prasad, Anshul Shakya, Sushant K. Shrivastava, Nilambari Gurav, Rupali S. Prasad

2020Journal of Biomolecular Structure and Dynamics121 citationsDOIOpen Access PDF

Abstract

= -89.42 kcal/mol) as the most promising inhibitor. During MD studies, the molecule optimizes its conformation for better fitting with the receptor active site justifying the high binding affinity. Based on proven therapeutic, that is, immunomodulatory, antioxidant and anti-inflammatory roles and plausible potential against n-CoV-2 proteins, Indian ginseng could be one of the alternatives as an antiviral agent in the treatment of COVID 19. Communicated by Ramaswamy H. Sarma.

Topics & Concepts

Docking (animal)Withania somniferaIn silicoGinsengBiologyBinding siteVirtual screeningChemistryBiochemistryComputational biologyDrug discoveryMedicineGenePathologyAlternative medicineNursingPhytochemicals and Medicinal PlantsAndrographolide Research and ApplicationsComputational Drug Discovery Methods
Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an <i>in-silico</i> approach | Litcius